How effective is Bosutinib?

Bosutinibis areceptor tyrosine kinase inhibitor, and Bosutinib is suitable for treatmentAdult and pediatric patients 1years old and 1years old and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) who are newly diagnosed or who are resistant or intolerant to previous treatments. It is also indicated for the treatment of adult patients with accelerated-phase or blast-phase Philadelphia chromosome-positive chronic myelogenous leukemia who are newly diagnosed or who are resistant or intolerant to prior therapy.

Safety population (Received at least 1doseBOSULIF)includes:Two hundred and sixty-eight(268)newly diagnosedCP The median duration of CMLpatients receivingbosutinib was 14.1 months(Range:0.3 span> to 24.7months), with a median dose intensity of 391.8mg/days. The treatment effect is quite optimistic.

In clinical studies, it was observed that higher bosutinib exposures were associated with greater likelihood of reactions and greater likelihood of safety events. The time course of the pharmacodynamic response to bosutinib has not been fully determined. As a single oral dose of 500 mg bosutinib and ketoconazole (a strong inhibitor of CYP3A), bosutinib does not prolong the QT interval to any clinically relevant extent. Bosutinib protein binding is 94% in vitro and 96% in vitro and is independent of concentration. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0